Telesis Bio

Update in progress

TBIO (OTC Markets OTCPK)

Company RatingNeutral
SectorHealthcare
IndustryMedical Devices

Telesis Bio, Inc. is a synthetic biology company that manufactures and sells instruments, reagents, and related services for pharmaceutical and academic labs worldwide. Its BioXp systems enable digital DNA to end‑product DNA and mRNA with onboard NGS library prep, plus the BioXp Portal for design and assembly. It also offers De Novo kits, Select kits, NGS kits, benchtop reagents, and Gibson assembly tools. It licenses with Regeneron and serves govs, CROs, and biotech firms. Formerly Codex DNA, it began in 2011 and is based in San Diego.

Company score

Sentiment: 0.39; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.00; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.00; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.19; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive